Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 106 |
| Active Pipeline (Recruiting Now) | 49 (33) |
| Completed vs Stopped Early | 36 / 16 (15.1%) |
| Median Closed Actual Enrollment | 27 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Brigham and Women's Hospital | Boston, MA | 82 |
| Dana-Farber Cancer Institute | Boston, MA | 4 |
| Washington University and Siteman Cancer Center | Saint Louis, MO | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06096259 | Preventing Injured Knees From osteoArthritis: Severity Outcomes | Phase II | RECRUITING |
| NCT04025372 | INTREPId (INTermediate Risk Erection PreservatIon Trial) | Phase II | ACTIVE NOT RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Mass General Brigham across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Brigham and Women's Hospital Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.